PubMed Health⌕ Search

Biomedical subjects

Badrinath R Konety

Publications and source records attributed to Badrinath R Konety.

At least 19 recordsLinked to original sources
PubMed2007

Factors affecting outcomes after radical cystectomy in African Americans.

BACKGROUND: Previous studies indicate that African Americans with bladder cancer have a worse outcome than Caucasians. Delay in seeking care and higher stage at presentation have been cited as possible reasons for the observed differences. The authors hypothesized that differences in hospital volume where patients undergo radical cystectomy may be responsible for race-based differences in outcomes after the procedure. METHODS: The authors analyzed data from the Health Care Cost and Utilization Project and identified 4862 patients who had undergone radical cystectomy between 1998 and 2002. In-hospital mortality, complications, and length of stay (LOS) in hospital were compared between patients grouped by race. Hospitals were categorized into tertiles by the average number of radical cystectomies performed per year (1-4 radical cystectomies, 5-10 radical cystectomies, and >10 radical cystectomies). Univariate and multivariate analyses were performed to determine predictors of mortality, complications, LOS, and the likelihood that patients would undergo cystectomy at a high/medium-volume hospital. RESULTS: African Americans had the highest in-patient mortality, complications, and LOS after radical cystectomy. They also were the least likely to undergo radical cystectomy at a high/medium-volume hospital. When the analyses were controlled for potential confounding factors, there was no difference in in-hospital mortality by race, but differences persisted in the other 3 outcome variables. African Americans had higher odds of complications (odds ratio [OR], 1.57; P = .001), longer LOS (25%; P = .001), and lower odds of undergoing cystectomy at a high/medium-volume hospital (OR, 0.74; P = .03) compared with Caucasians. CONCLUSIONS: Race was an important factor in determining outcomes after radical cystectomy for bladder cancer. African Americans were less likely to undergo cystectomy at a high-volume hospital, thereby placing them at a higher risk of postoperative complications which ultimately may affect their survival.

Black or African American↗
PubMed2007

Influence of post-cystectomy complications on cost and subsequent outcome.

PURPOSE: Of commonly performed urological cancer procedures radical cystectomy is associated with the highest morbidity and mortality. The impact of each individual type of complication or a combination of them on various outcome measures, such as mortality, charges and length of stay, is unclear. We quantified the impact of specific post-cystectomy complications and combinations thereof in terms of mortality, charges and length of stay. MATERIALS AND METHODS: All 6,577 patients undergoing radical cystectomy for bladder cancer were identified from the Nationwide Inpatient Sample of the Healthcare Cost and Utilization Project (1998 to 2002). The prevalence of different International Classification of Diseases, 9th Revision, Clinical Modification coded complications following cystectomy were determined. Outcome variables of interest were in-hospital mortality, total charges and length of stay. The association between types of complications and measured outcomes were examined using univariate and multivariate regression models. The cumulative impact of multiple complications and various combinations of complications on outcomes was also examined. RESULTS: The overall complication rate was 28.4% in 1,869 cases and the mortality rate was 2.6%. Median total charges was 41,905 dollars and median length of stay was 9 days. Overall 20.7% of patients had 1, 6.1% had 2, 1.2% had 3 and 0.42% had greater than 3 complications. At least 1 complication almost doubled the odds of mortality and increased median total charges and length of stay by 15,000 dollars and 4 days, respectively. We defined expected levels of increase in the various outcome measures with increasing numbers of complications. The combination of postoperative infection and respiratory complication had the greatest impact on mortality, while the combination of wound and urinary tract infection had the greatest impact on length of stay and total charges. CONCLUSIONS: Although most patients undergoing cystectomy are older and have multiple comorbidities, the postoperative complications with the most significant impact were those directly related to surgery (primary complications). Secondary complications (cardiac, respiratory, vascular, etc) appear to have less of an impact on most common outcome measures. Hence, the greatest gains can be achieved by limiting primary complications. These data could be used to develop benchmarks of expected levels of primary and secondary complications after cystectomy.

Costs and Cost Analysis↗
PubMed2006

PSA screening among elderly men with limited life expectancies.

CONTEXT: Most guidelines do not recommend prostate-specific antigen (PSA) screening in elderly men who have limited life expectancies because the known harms of screening outweigh potential benefits. However, there are no large-scale studies of actual PSA screening practices in elderly men, according to life expectancy. OBJECTIVE: To characterize the extent of PSA screening among elderly men, including those with limited life expectancies. DESIGN, SETTING, AND PARTICIPANTS: Cohort study of 597 642 male veterans aged 70 years and older who were seen at 104 US Department of Veterans Affairs facilities during both 2002 and 2003, without a history of prostate cancer, elevated PSA, or prostate cancer symptoms. Charlson comorbidity scores were used to stratify men into 3 groups ranging from best health (score = 0) to worst health (score >or= 4). MAIN OUTCOME MEASURE: Receipt of PSA testing during 2003 was based on US Department of Veterans Affairs data and Medicare claims. RESULTS: In 2003, 56% of elderly men had a PSA test performed. Although PSA screening rates decreased with advancing age, within each 5-year age group the percentage of men who underwent a PSA test did not substantially decline with worsening health. For example, among men aged 85 years and older, 34% in best health had a PSA test compared with 36% in worst health. In multivariate analyses, many nonclinical factors, such as marital status and region of the country, had a greater effect on PSA screening than health, and screening rates exceeded 60% for some subgroups of men in worst health. CONCLUSIONS: Prostate-specific antigen screening rates among elderly veterans with limited life expectancies should be much lower than current practice given the known harms of screening. More attention to prognosis is needed when making screening PSA recommendations to elderly men.

Aged↗
PubMed2006

Practice patterns in screening and management of prostate cancer in elderly men.

OBJECTIVES: To determine the practice preferences for prostate cancer screening and treatment in men 75 years of age or older among healthcare providers in Iowa. METHODS: Practice patterns were determined by an institutional review board-approved 15-item survey mailed to all 3105 Iowa healthcare providers who care for older men. A modified Dillman method was used for the survey. Actual prostate-specific antigen (PSA) testing practices derived from our institutional database were correlated with the survey data. RESULTS: The survey yielded a response rate of 32% (997 respondents). Of the respondents, 96% of primary care physicians and 97% of urologists preferred to stop PSA-based prostate cancer screening by age 80. This was compatible with our institutional data that indicated a PSA testing rate of 5.2% in men 80 years or older. Most physicians used the digital rectal examination as the first test for screening and reported a lack of educational materials to provide to patients. Older physicians and family practitioners were more likely to continue prostate cancer screening beyond 75 years, and most consented to patient requests for screening. CONCLUSIONS: The predilection for prostate cancer screening among healthcare providers declines with increasing patient age but persists for a small proportion of patients. The education of both patients and healthcare providers to more selectively screen men older than 75 years and the development of educational materials are needed. A consensus among healthcare providers would facilitate adoption of a tailored approach to managing prostate cancer in older men, thereby decreasing healthcare costs and morbidity while limiting the use of unnecessary therapy.

Adult↗
PubMed2006

Complications after radical cystectomy: analysis of population-based data.

OBJECTIVES: To determine the morbidity and mortality from radical cystectomy in a nationally representative population-derived sample. Complications after radical cystectomy have been reported from large single-institution series but population-based representative data are lacking. METHODS: All patients undergoing radical cystectomy for bladder cancer were identified from the National Inpatient Sample data set of the Health Care Utilization Project (1998 to 2002). The prevalence of different complications coded according to the International Classification of Diseases, version 9, after cystectomy were determined. Independent hospital and patient-related factors associated with the occurrence of a complication were determined by logistic regression analysis. The prevalence of complication by type and frequency were compared with that in other large reported series. RESULTS: The in-hospital mortality rate was 2.57%, and at least one complication other than death occurred in 28.4% of patients. These rates were comparable to those reported in published studies. Younger patients had a lower likelihood of complications. Younger patients and those undergoing cystectomy at large bed size, urban, teaching hospitals were less likely to have secondary complications after surgery, and younger patients, women, and those undergoing cystectomy at high-volume hospitals were less likely to have primary complications directly related to their surgery. CONCLUSIONS: The overall morbidity and mortality rates after radical cystectomy in a population-based sample were comparable to those reported from individual centers. Larger centers in urban locations may have lower complication rates but only hospitals performing a high volume of cystectomies were associated with fewer primary surgery-related complications.

Aged↗
PubMed2006

Impact of extent of lymphadenectomy on survival after radical prostatectomy for prostate cancer.

OBJECTIVES: Controversy exists regarding the benefit of extended lymphadenectomy at radical prostatectomy for prostate cancer. We sought to determine whether more extended lymphadenectomy, along with radical prostatectomy, resulted in a decreased risk of prostate cancer-specific death at 10 years. METHODS: Data on all patients undergoing radical prostatectomy (with or without lymphadenectomy) for prostate cancer obtained from the Surveillance, Epidemiology, and End Results Program (1988 to 1991) were examined. All surviving patients had a minimal follow-up of 10 years. Multivariate Cox proportional hazards analysis was used to determine the independent effect of lymphadenectomy on the risk of prostate cancer-specific death. RESULTS: Patients undergoing excision of at least 4 lymph nodes (node-positive and node-negative patients) or more than 10 nodes (only node-negative patients) had a lower risk of prostate cancer-specific death at 10 years than did those who did not undergo lymphadenectomy. The removal of a greater number of nodes was associated with a greater likelihood of the presence of positive nodes. The presence of more than one positive node was associated with a greater risk of prostate cancer-related death. CONCLUSIONS: Performing more extensive pelvic lymphadenectomy in patients undergoing radical prostatectomy could improve the accuracy of staging and reduce the risk of prostate cancer-specific death in the long term.

Adult↗
PubMed2006

Quality of life in long-term survivors of bladder cancer.

BACKGROUND: The quality of life (QOL) of long-term survivors of bladder cancer in a population-based registry was assessed. METHODS: The Functional Assessment of Cancer Therapy (FACT-BL) instrument was used to evaluate QOL in a population-based sample of bladder cancer patients. QOL scores were compared between those undergoing radical cystectomy (RC) or those with an intact bladder (BI) and between continent and conduit urinary diversion groups. The influence of current age and time since diagnosis of cancer on QOL were also examined. Multivariate regression analyses were performed to examine the influence of age, time since diagnosis, current condition, treatment, stage of cancer, and comorbid conditions on QOL. RESULTS: A total of 259 patients participated in the study who had undergone RC (n=82) or other therapy (BI) (n=177). There were no differences in general QOL scores between RC and BI groups and between the 2 urinary diversion groups, but patients undergoing RC had worse sexual function scores. QOL scores for BI patients tended to decrease with increasing age (P=.01). Presence of comorbid conditions lowered QOL (P<.05). CONCLUSIONS: General QOL does not vary among long-term bladder cancer survivors regardless of treatment, but sexual functioning can be adversely affected in those undergoing cystectomy. Long-term QOL declines even in those with intact bladders, particularly in those with comorbidities.

Aged↗
PubMed2006

Characteristics of patients and predictors of in-hospital mortality after hospitalization for head and neck cancers.

BACKGROUND: The objectives of this study were to describe the characteristics of patients who were hospitalized for head and neck cancer (HNC) during the years 2000 through 2003 and to identify predictors of in-hospital mortality. METHODS: The Nationwide Inpatient Sample for the years 2000 through 2003 was used. All patients who had a primary diagnosis of any of the HNCs were included in the study. Univariate and multivariate logistic regression analyses were used to identify patient and hospital characteristics that were associated with in-hospital mortality. RESULTS: In total, 24,803 patients were hospitalized for HNCs. The average age of patients was 62 years, the mean length of stay in the hospital was 7.89 days, and the in-hospital mortality rate was 5.18%. Patients who had comorbid conditions and complications and patients who were grouped under the self-pay/no charge/others category had greater odds of in-hospital mortality compared with patients who were covered by private insurance (P<.02). Patients who were treated in large-bed, urban, or teaching hospitals had lower odds of in-hospital mortality compared with patients who were treated in small or medium-bed, rural, or nonteaching hospitals, respectively (P<.03). CONCLUSIONS: Patients with comorbid conditions and complications and patients without adequate insurance coverage had greater odds of in-hospital mortality. One reason for this may be inadequate access to care because of the absence of insurance or underinsurance. Further studies controlling for disease stage will be required to determine whether insurance status and patient-related factors can influence outcomes from HNC in individual patients independent of their disease stage.

Aged↗
PubMed2006

Mortality after major surgery for urologic cancers in specialized urology hospitals: are they any better?

PURPOSE: Specialty-specific hospitals and hospitals with a high volume of complex procedures have been shown to have better outcomes. We sought to determine whether a high volume of unrelated complex procedures or procedures in the same specialty area (urology) could translate into better outcomes after major urologic cancer surgery. METHODS: We performed a cross-sectional analysis of administrative discharge abstract data from the Nationwide Inpatient Sample of the Health Care Utilization Project for years 1998 to 2002. Comparison of outcome after three major urologic cancer-related surgical procedures (radical cystectomy [RC], radical nephrectomy [RN], and radical prostatectomy [RP]) at hospitals by procedure-specific volume, specialized urology status, and Leapfrog criteria was obtained to determine in-hospital mortality after the procedure. All patients in the database with a diagnosis of bladder, kidney, or prostate cancer being admitted for RC, RN, or RP between 1998 and 2002 were included. RESULTS: Neither specialized urology status nor meeting Leapfrog volume criteria for unrelated procedures was associated with lower odds of in-hospital mortality after any of the procedures examined. High-volume hospitals (for RC and RP) and moderate-volume hospitals (for RP) were associated with lower odds of mortality. None of the examined hospital volume-related factors was associated with lower odds of mortality after RN. CONCLUSION: In-hospital mortality after two of three major urologic cancer procedures is affected only by procedure-specific volumes. Generalized process measures existing in hospitals performing a high volume of general urologic procedures or unrelated complex procedures may be less important determinants of procedure-specific outcomes in patients.

Cross-Sectional Studies↗
PubMed2006

Cutaneous metastases from transitional cell carcinoma of the bladder.

Cutaneous metastases from primary genitourinary malignancies are rare and usually represent a poor prognostic sign. Very few cases of skin metastases from urothelial carcinoma have been reported in the past, and most of them were treated with chemotherapy. We report a patient with transitional cell carcinoma of the bladder who developed skin metastases after cystectomy. The lesions did not respond to systemic chemotherapy but resolved with local radiation therapy. We discuss the need to have a high index of suspicion to identify these lesions and the treatment approaches.

Carcinoma, Transitional Cell↗
PubMed2006

Epigenetic inactivation of Wnt inhibitory factor-1 plays an important role in bladder cancer through aberrant canonical Wnt/beta-catenin signaling pathway.

PURPOSE: Aberrant activation of the Wingless-type (Wnt) pathway plays a significant role in the pathogenesis of several human cancers. Wnt inhibitory factor-1 (Wif-1) was identified as one of the secreted antagonists that can bind Wnt protein. We hypothesize that Wif-1 plays an important role in bladder cancer pathogenesis. EXPERIMENTAL DESIGN: To test this hypothesis, epigenetic and genetic pathways involved in the Wif-1 gene modulation and expression of Wnt/beta-catenin-related genes were analyzed in 4 bladder tumor cell lines and 54 bladder tumor and matched normal bladder mucosa. RESULTS: Wif-1 mRNA expression was significantly enhanced after 5-aza-2'-deoxycytidine treatment in bladder tumor cell lines. Wif-1 promoter methylation level was significantly higher and Wif-1 mRNA expression was significantly lower in bladder tumor samples than in bladder mucosa samples. In the total bladder tumor and bladder mucosa samples, an inverse correlation was found between promoter methylation and Wif-1 mRNA transcript levels. However, loss-of-heterozygosity at chromosome 12q14.3 close to the Wif-1 gene loci was a rare event (3.7%). Nuclear accumulation of beta-catenin was significantly more frequent in bladder tumor than in bladder mucosa and inversely correlated with Wif-1 expression. In addition, known targets of the canonical Wnt/beta-catenin signaling pathway, such as c-myc and cyclin D1, were up-regulated in bladder tumor compared with bladder mucosa, and this up-regulation was associated with reduced Wif-1 expression at both mRNA and protein levels. Furthermore, transfection of Wif-1 small interfering RNA into bladder tumor cells expressing Wif-1 mRNA transcripts had increased levels of c-myc and cyclin D1 and accelerated cell growth. CONCLUSION: This is the first report showing that CpG hypermethylation of the Wif-1 promoter is a frequent event in bladder tumor and may contribute to pathogenesis of bladder cancer through aberrant canonical Wnt/beta-catenin signaling pathway. The present study elucidates novel pathways that are involved in the pathogenesis of bladder cancer.

Adaptor Proteins, Signal Transducing↗
PubMed2006

The impact of age on the response of patients with superficial bladder cancer to intravesical immunotherapy.

PURPOSE: We determined the influence of age on response to intravesical immunotherapy in patients with superficial bladder cancer. MATERIALS AND METHODS: Data from a national phase II multicenter trial for BCG plus IFN-alpha intravesical therapy for superficial bladder cancer were analyzed. Recurrence-free survival 2 years after the initiation of therapy was examined in patients by incremental age decade. BCG-N patients received 81 mg BCG and 50 MU IFN-alpha, while patients who had previously been treated with BCG received a third of the BCG dose with 50 MU IFN-alpha and those who were BCG intolerant received a tenth of the BCG dose with 100 MU IFN-alpha. Kaplan-Meier survival curves were obtained. RESULTS: In all patients the largest difference in response was between the 289 who were 61 to 70 years old and the 123 who were older than 80 years with a 22% difference in cancer-free survival at a median followup of 24 months (61% vs 39%, p = 0.0002). When we assessed BCG-N and BCG treated patients separately in the 2 age groups, patients older than 80 years had a persistently lower response rate than younger patients 61 to 70 years old. Of BCG-N patients those older than 80 and younger than 50 years had the lowest cancer-free survival at a median followup of 24 months (47% and 45%, respectively). On multivariate analysis age was an independent risk factor for response. CONCLUSIONS: Aging appears to be associated with a decreased response to intravesical immunotherapy and is particularly apparent in patients older than 80 years. A potential explanation could be their depressed baseline immune status and consequent inability to mount an immune reaction to BCG or IFN-alpha.

Adjuvants, Immunologic↗
PubMed2006

Prevalence of prostate specific antigen testing for prostate cancer in elderly men.

PURPOSE: We investigated the prevalence and outcome of PSA testing for prostate cancer screening or diagnosis in elderly men 75 years or older at our academic medical center. MATERIALS AND METHODS: A cross-sectional study design was used to identify all men 75 years or older who underwent a PSA test through the family medicine or internal medicine service at our institution between January 1, 1998 and June 30, 2004. All patients with a suspected (PSA less than 0.1 ng/ml) or confirmed prior diagnosis of prostate cancer were excluded. The prevalence of PSA testing was then compared to that in younger age groups (45 to 54, 55 to 64 and 65 to 74 years). We then examined the frequency and nature of further evaluation and treatment performed in men following the PSA test. RESULTS: The 8,787 male patients who were 75 years or older generated a total of 82,672 visits in the 5.5-year period. Of these patients 505 (5.7%) underwent at least 1 PSA test. The prevalence of PSA testing in the younger age groups was 10.3% (1,769 of 17,175) in patients 45 to 54 years old, 14.9% (2,052 of 13,772) in those 55 to 64 years old and 11.8% (1,258 of 10,661) in those 65 to 74 years old (chi-square test p <0.001). Of these patients 98 of 343 (28.6%) with PSA between 0.1 and 4 ng/ml were referred to a urologist at our institution and 3 underwent biopsy. None had a prostate cancer diagnosis. Of the 162 patients with PSA more than 4 ng/ml 84 (51.9%) were referred to a urologist. Only 10 of the 84 patients (11.9%) who were referred to a urologist underwent prostate biopsy. Six of the 10 men (60%) were diagnosed with prostate cancer, including 1 with a Gleason 6 tumor, 1 with a Gleason 7 tumor and 4 who were found to have tumors with a Gleason score of 8 or greater. All patients received androgen deprivation therapy, except 1 who received local external beam radiation therapy. An additional patient was diagnosed by biopsy of a vertebral lesion and he received hormone therapy. At a median followup of 51 months (range 28 to 72) 4 of 7 men (57%) were alive with disease. CONCLUSIONS: PSA testing for prostate cancer screening and diagnosis appear to decrease with advancing age. A small but significant proportion of men who are 75 years or older continue to undergo PSA testing. Abnormal PSA results do not always result in further evaluation and therapy for prostate cancer in elderly men. The establishment of firm guideline recommendations regarding PSA testing and further evaluation for prostate cancer in elderly men, perhaps based on individualized geriatric assessment, may be helpful.

Aged↗
PubMed2006

Does the interval between prostate biopsy and radical prostatectomy affect the immediate postoperative outcome?

OBJECTIVE: To determine whether the interval between prostate biopsy and radical prostatectomy (RP) affects the immediate postoperative outcome. PATIENTS AND METHODS: The study was a retrospective chart review of 169 patients who had retropubic RP at our institution. Using a series of univariate and multivariate logistic regression analyses, we evaluated whether the interval between biopsy and RP was a significant independent predictor of operative duration, estimated blood loss, transfusion rate, nerve-sparing (yes/no), positive margin rate, length of stay, complications, and urinary continence after RP. RESULTS: The interval from biopsy to RP was 14-378 days; there were no significant differences in operative duration, estimated intraoperative blood loss, nerve-sparing rate, transfusion rate and amount, hospitalization time, positive margin rate, major postoperative complications, and continence in patients with biopsy to RP intervals above and below the median. The biopsy to RP interval was not an independent predictor of outcomes during or after RP. There were no direct or indirect correlations between biopsy to RP interval and any of the postoperative outcomes. CONCLUSION: The interval between prostate biopsy and retropubic RP appears to have no effect on immediate postoperative outcomes. We were unable to determine a specific minimum required interval beyond 2 weeks after prostate biopsy before proceeding with RP.

Aged↗
PubMed2006

Diagnostic Utility of the ImmunoCyt/uCyt+ Test in Bladder Cancer.

Bladder cancer is a common malignancy in the United States. Although urine cytology is a useful adjunct in both diagnosis and follow-up and is highly sensitive for detecting high-grade tumors, it is limited by decreased sensitivity in detecting low-grade tumors, which constitute the majority of new diagnoses. Additional screening tests with high sensitivity and specificity for urothelial tumors of all grades are indicated to help improve the diagnostic ability of urine cytology as well as to reduce the need for frequent cystoscopies, especially in those with low-risk disease. Several assays have been developed, with the ImmunoCyt/uCyt+ test (DiagnoCure, Inc., Québec, Canada) being especially promising. Recent studies on the applicability and efficacy of ImmunoCyt/uCyt+ testing are reviewed, as are its sensitivity, specificity, and predictive value in the follow-up and screening of urothelial malignancies.

Journal Article↗
PubMed2005

Effect of axillary lymphadenectomy on breast carcinoma survival.

PURPOSE: To determine the effect of axillary lymphadenectomy on breast carcinoma survival, and to determine racial and age differences in the extent of axillary lymphadenectomy. METHODS: Cases were 257,157 women diagnosed with breast carcinoma in the Surveillance, Epidemiology and End Results program from 1988 through 2000. Variables included number of lymph nodes removed, number of positive lymph nodes, ratio of positive nodes to number of nodes removed, use of radiation therapy, surgery (breast conserving surgery versus mastectomy), stage, age, race, and hormone receptor status. Correlation statistics were used to determine associations between survival and lymph node variables for all cases and when stratified by stage. Kaplan-Meier survival analyses were used to compare survival by lymph node categories overall and stratified by stage. Cox regression analyses were used to determine factors associated with survival. RESULTS: Older women were significantly less likely to have lymph nodes examined and lymph node involvement compared to younger women, and black women were significantly less likely to have lymph nodes examined, but were significantly more likely to have lymph node involvement compared to white women. Risk of death was significantly reduced for cases who had lymphadenectomy compared to those who did not. For cases diagnosed at stage IIA or higher, risk of death increased significantly with increased number of positive nodes and increased ratio of positive to total nodes removed. CONCLUSIONS: Improved survival in node negative cases of breast carcinoma may be due to removal of undetected micrometastases. Women diagnosed at more advanced stages as well as black women may also benefit from more extensive lymphadenectomy.

Adult↗